erlotinib hydrochloride has been researched along with propidium in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (propidium) | Trials (propidium) | Recent Studies (post-2010) (propidium) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 2,877 | 10 | 934 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | propidium (IC50) |
|---|---|---|---|
| Cholinesterase | Homo sapiens (human) | 6.289 | |
| Acetylcholinesterase | Homo sapiens (human) | 6.289 | |
| Acetylcholinesterase | Bos taurus (cattle) | 6.289 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, CH; Chen, MC; Liou, JP; Pan, SL; Teng, CM; Tsai, AC; Wang, JC | 1 |
1 other study(ies) available for erlotinib hydrochloride and propidium
| Article | Year |
|---|---|
The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells.
Topics: Acetylation; Animals; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Indoles; Lung Neoplasms; Mice; Mice, Nude; Propidium; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |